Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
Phase 3
Terminated
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 3173
- Registration Number
- NCT01656434
A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 360
- Registration Number
- NCT01617187
Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)
Phase 2
Withdrawn
- Conditions
- Asthma
- Interventions
- Drug: MF/F Metered Dose Inhaler (MDI) 25/5 mcgDrug: MF/F MDI 50/5 mcgDrug: MF/F MDI 100/5 mcgDrug: BDP hydrofluoroalkane (HFA) 80 mcg
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01615874
A Study of the Effect of Ezetimibe on Glucose Metabolism in Type 2 Diabetics With Hypercholesterolemia (P06541)
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 152
- Registration Number
- NCT01611883
An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
Phase 3
Withdrawn
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01599494
A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Organon and Co
- Registration Number
- NCT01587235
A Study of the Patterns of Use of Etoricoxib in France (MK-0663-148)
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 547
- Registration Number
- NCT01572675
Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 49
- Registration Number
- NCT01566149
Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis
Phase 3
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- First Posted Date
- 2012-03-14
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 239
- Registration Number
- NCT01554163
A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo Dry Powder Inhaler (DPI)Drug: Placebo Metered Dose Inhaler (MDI)
- First Posted Date
- 2011-12-30
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 583
- Registration Number
- NCT01502371